Select Bibliography

Filter by any of these (after searching):

Giri, S

AUTHOR ABSTRACT DEADLINES

A meeting abstract must be submitted by the first or corresponding author to the Alliance Publications Coordinator (publications@AllianceNCTN.org) at least two weeks prior to the meeting abstract submission deadline. For detailed information about Alliance Publications guidelines, please refer to the policies, along with the author abstract deadlines.

There are 6 items

Randomized Phase II/III Study of DA-EPOCH-R +/- Venetoclax in Previously Untreated Double Hit Lymphoma: Initial Results from Alliance A051701

Abramson, Jeremy S. , Ruppert, Amy S. , Giri, Sharmila , Hudson, Ann ... - ASH - Blood - 2021

Abstract - Primary - Preliminary - Lymphoma - A051701

Myeloablative versus non-myeloablative consolidative chemotherapy for newly diagnosed primary central nervous system lymphoma: Results of induction therapy in CALGB 51101 (Alliance)

Batchelor, T , Giri, S , Stark, A , Bartlett, N , Hsi, E , Cheson, B ... - ASCO - J Clin Oncol - 2020

Abstract - Primary - Primary - Lymphoma - CALGB-51101

Myeloablative versus non-myeloablative consolidative chemotherapy for newly diagnosed primary central nervous system lymphoma: Results of CALGB 51101 [Alliance]

Batchelor, Tracy T. , Giri, Sharmila , Ruppert, Amy S. ... - ICBTRT - - 2021

Abstract - Primary - Primary - Lymphoma - CALGB-51101

Myeloablative versus non-myeloablative consolidative chemotherapy for newly diagnosed primary central nervous system lymphoma: Results of CALGB 51101 [Alliance]

Batchelor, Tracy T. , Giri, Sharmila , Ruppert, Amy S. ... - ASCO - J Clin Oncol - 2021

Abstract - Primary - Primary - Lymphoma - CALGB-51101

Analysis of Transplant-eligible Patients (Pts) Who Received Front-line Daratumumab (DARA)-based Therapy for Treatment of Newly Diagnosed Multiple Myeloma (NDMM) With High-risk Cytogenetic Abnormalities (HRCA) in the GRIFFIN (AFT-29) and MASTER Studies

Callander, Natalie S. , Silbermann, Rebecca , Kaufman, Jonathan L. ... - ASH - Blood - 2022

Abstract - Secondary-not-in-original - Primary - Myeloma - AFT-29 (GRIFFIN) , MASTER

Biomarkers for Risk Stratification in Patients with Previously Untreated Follicular Lymphoma Receiving Anti-CD20-Based Biologic Therapy

Sohani, Aliyah R. , Maurer, Matthew J. , Giri, Sharmila ... - - Am J Surg Pathol - 2021

Manuscript - Secondary-not-in-original - Meta-Analysis - Correl Sci NOS - CALGB-50402 , CALGB-50701 , CALGB-50803 , CALGB-50901